Medicare's pilot GLP-1 discount program has a catch. Some sick patients don't qualify

Medicare launched a pilot program that could streamline the process to get GLP-1s, with some seniors paying just $50 a month. But many people with the most serious illnesses won't get that discount.

The top 3

  1. Top-Selling GLP-1 Medications Globally: Eli Lilly's tirzepatide (Mounjaro/Zepbound) and Novo Nordisk's semaglutide (Ozempic/Wegovy/Rybelsus) are the leading GLP-1 drugs, dominating the market with multi-billion dollar sales.
  2. Most Costly Medical Conditions in the US: Type 2 diabetes, cardiovascular diseases, and musculoskeletal disorders are among the most expensive medical conditions in the US, collectively costing hundreds of billions annually.
  3. Key Milestones in Diabetes Treatment History: The history of diabetes treatment spans millennia, but the most transformative breakthroughs occurred in the last century, starting with insulin and progressing to oral medications and GLP-1 agonists.

Sources

Open the full topic